Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

26
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
26
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.7K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.

Nature communications·2026
Same author

An adaptive cellular source of IL-17A and IL-17F is critical for the induction of experimental autoimmune encephalomyelitis.

Science immunology·2026
Same author

The dual role of TOX in regulating T<sub>H</sub>1 and CD8<sup>+</sup> T cell fate.

Nature immunology·2026
Same author

Author Correction: Circadian circuits control plasticity of group 3 innate lymphoid cells by sustaining epigenetic configuration of RORγt.

Nature immunology·2026
Same author

Molecular Mechanisms Driving Metastatic Progression Within the Aged Tumor Microenvironment.

International journal of molecular sciences·2025
Same author

Circadian circuits control plasticity of group 3 innate lymphoid cells by sustaining epigenetic configuration of RORγt.

Nature immunology·2025
Same journal

Regulation of solid tumors by the peripheral nervous system.

The Journal of experimental medicine·2026
Same journal

Friend or foe? IFNλ drives fibrosis.

The Journal of experimental medicine·2026
Same journal

BAd-looking or CHarming: The two faces of BACH2.

The Journal of experimental medicine·2026
Same journal

Bridging veins govern discrepancy of CSF efflux into dura mater in mice.

The Journal of experimental medicine·2026
Same journal

Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation.

The Journal of experimental medicine·2026
Same journal

Interferon-λ drives renal fibrosis by coordinating epithelial-fibroblast crosstalk.

The Journal of experimental medicine·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Inhibitory receptor agonists: Emerging strategies in immune modulation.

Kieran R Adam1,2,3, Aamir Suhail4,5,6, Vijay K Kuchroo4,5,6

  • 1Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

The Journal of Experimental Medicine
|March 31, 2026
PubMed
Summary
This summary is machine-generated.

Agonistic antibodies targeting inhibitory receptors (IRs) show promise for treating autoimmune diseases by promoting immune tolerance. These therapies harness IR signaling to suppress harmful immune responses, offering new treatment avenues.

More Related Videos

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

954
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

13.1K

Related Experiment Videos

Last Updated: Apr 1, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

954
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

13.1K

Area of Science:

  • Immunology
  • Immunotherapy
  • Autoimmunity

Background:

  • Inhibitory receptors (IRs) like CTLA-4, PD-1, LAG3, TIM-3, and TIGIT regulate immune homeostasis and prevent autoimmunity.
  • IR blockade revolutionized cancer immunotherapy by enhancing anti-tumor T cell responses.
  • Emerging strategies explore harnessing IRs for autoimmune and inflammatory diseases.

Purpose of the Study:

  • To review recent advancements in agonistic IR-targeted therapies for autoimmune and inflammatory disorders.
  • To examine the mechanisms of action, efficacy, and translational challenges of these novel therapies.

Main Methods:

  • Literature review of preclinical and clinical studies on agonistic IR antibodies.
  • Analysis of IR signaling pathways and their role in immune tolerance.
  • Evaluation of therapeutic efficacy in autoimmune disease models.

Main Results:

  • Agonistic IR antibodies promote immune tolerance and suppress pathological T cell functions in preclinical models.
  • These therapies demonstrate potential for managing autoimmunity and inflammation.
  • Significant translational challenges remain for clinical application.

Conclusions:

  • Agonistic IR-targeted therapies represent a promising frontier for treating autoimmune and inflammatory conditions.
  • Further research and clinical development are needed to overcome translational hurdles.
  • Harnessing IRs offers a novel approach to immune modulation in disease management.